3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
9
Breast Neoplasms
7
Obesity
4
Colorectal Neoplasms
4
Rectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Radiation Injuries
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Weight Loss
1
Uterine Cervical Dysplasia
1
Stage IV Breast Cancer AJCC v6 and v7
1
Sezary Syndrome
1
Sexuality
1
Sexual Dysfunction, Physiological
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Patient Compliance
1
Overweight
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
Diet Therapy
×
Clear all
NCT05237921
2024-03-19
CEDI
Hospital Beatriz Ângelo
Phase NA
Completed
50 enrolled